When no bridging process can be found, Pfizer donates the medicines to hospitals that request it. Half of Pfizer’s investments are done through donations, as a…
In Conversation
Romania can be seen as a very attractive market for the pharmaceutical industry: a population of 20 million, high levels of unmet medical need and as…
Our clients always stress how hard it is for them to have the lowest prices in Europe while paying a clawback tax of over 20 percent…
[Infrastructure, education, and healthcare] are the key to better serving the Romanian citizens and making the country more attractive
We are passing through difficult times for generics companies in Romania
Comparing the Czech Republic with other markets in EE, I would say that the country provides a solid landscape for the introduction of new products and…
Romania needs to find alternative sources of funding and requires more effective management of the current budget
Even though the consumption of medicines per capita [in Romania] is still lower than the European average, we are catching up
Increasingly, medicines are putting pressure on public funds, that is why companies must contribute to facilitating patient access to treatment in accordance with the applicable legislation
Accord provides one-third of the oncological treatments in Europe which makes it the continent's leading supplier of oncology products. In Romania, oncology and haematology are the…
Building a highly skilled labour force in Romania is becoming increasingly difficult due to the ‘brain drain’ phenomenon and a lack of attractiveness in the Romanian…
Here in Romania, the main challenge is visibility on timelines
